A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂
基本信息
- 批准号:10687871
- 负责人:
- 金额:$ 56.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAdultAffectAftercareAlkylating AgentsAnimal ModelAnimalsBrain NeoplasmsBypassCRISPR/Cas technologyCancer CenterCell LineCell SurvivalCellsChemotherapy and/or radiationClientClinicalClinical TrialsCombination Drug TherapyComplexCorrelative StudyDNADNA RepairDNA Repair GeneDataDefense MechanismsDevelopmentDevelopment PlansDrug KineticsEpidermal Growth Factor ReceptorEvolutionFundingFutureGenerationsGlioblastomaGliomaGrantGrowthHSP 90 inhibitionHeat shock proteinsHeat-Shock Proteins 90Heat-Shock ResponseHeterogeneityHumanIn VitroIndividualInstitutionInvadedMGMT geneMalignant NeoplasmsMalignant neoplasm of brainMaximum Tolerated DoseMediatingMediatorMethylationMicrodialysisMismatch RepairModelingMolecular ChaperonesMusNewly DiagnosedNormal CellOncogenicOncologyOncoproteinsOperative Surgical ProceduresOutcomePathway interactionsPatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacodynamicsPhasePhase I Clinical TrialsPlasmaPositioning AttributePrimary Brain NeoplasmsProcessProtein FamilyProteinsRadiation therapyRadiation-Sensitizing AgentsRandomizedRecurrenceRecurrent tumorResistanceRoleSamplingScheduleSerumSignal TransductionSliceSpecimenStressTissuesToxic effectTreatment FailureTumor TissueUp-RegulationZebrafishaggressive therapyangiogenesisantitumor effectblood-brain barrier crossingcancer cellchemoradiationchemotherapyco-clinical trialconventional therapycytotoxicds-DNAefficacy evaluationefficacy trialepidermal growth factor receptor VIIIglioma cell lineimprovedimproved outcomein vivoinhibitorinsightknock-downmembermigrationmouse modelneoplastic cellnovelnovel therapeutic interventionnovel therapeuticsoverexpressionpatient subsetspharmacokinetics and pharmacodynamicsphase 2 studyphase I trialphase II trialpre-clinicalprotein complexradiation effectresistance mechanismresponsestem cellstemozolomidetherapy outcometherapy resistanttranscriptometranscriptome sequencingtrial planningtumortumor growthtumor heterogeneity
项目摘要
PROJECT SUMMARY
Glioblastoma is a lethal primary brain tumor with limited treatment options. The current standard therapy with
combined chemoradiation therapy (chemoRT) with temozolomide (TMZ), an alkylating agent offers a median
survival of only 16-18 months. There is an urgent need for novel therapies especially those that can overcome
resistance to chemoRT. Cancer cells develop complex resistance mechanisms that enable them to survive the
effects of conventional therapies. One such evolutionally conserved mechanism is the heat shock response
(HSR) which can deploy several diverse defense processes in the setting of adverse environmental conditions.
The HSR is mediated by heat shock proteins (HSP), a class of molecular chaperones that shuttle and
configure client oncoproteins into proper functional states. In preliminary studies, we show that onalespib, a
novel long acting inhibitor of heat shock protein 90 (Hsp90), a critical mediator of the HSR in cancer cells,
blocked tumor growth, invasion and angiogenesis in gliomas suggesting the potential for a strong independent
antitumor effect. Relevant to this proposal, onalespib sensitizes glioma cells to TMZ and RT in patient-derived
(PDX) cell lines and in a zebrafish and mouse intracranial glioma animal models. Based on these data, in this
grant submission, we propose a phase I clinical trial through the NCI-funded Adult Brain Tumor Consortium to
identify the maximum tolerated dose of the combination of onalespib with chemoRT in adults with newly
diagnosed GBM. We also propose to conduct key correlative tissue and plasma studies through the following
specific aims: Aim 1 will identify the MTD of onalespib in combination of chemoRT and adjuvant temozolomide
and will determine whether onalespib can cross the blood brain barrier and achieve sufficient concentrations in
enhancing and non-enhancing glioma tissue compared with plasma levels. Aim 2 will determine the
pharmacodynamic effects of onalespib by assessing whether onalespib can inhibit Hsp90, its target, in human
GBM tissue obtained in this trial and whether this inhibition can affect its chaperone oncoprotein clients
particularly those relevant to DNA repair and cell survival against the effects of RT and TMZ. In Aim 3, we will
conduct co-clinical trials using PDX intracranial glioma models and organotypic human glioma slices to
determine the mechanisms of sensitivity and resistance to onalespib effects to provide insights that can help
modify the subsequent phase II trial. This is the first human trial of an Hsp90 inhibitor in brain tumors and the
first to combine an Hsp90 inhibitor with chemo- and radiation therapy against GBM. Successful completion of
this trial will enable us to proceed to a Phase II efficacy trial (approved by NRG oncology) and will provide
comprehensive PK and PD data that can help the development of onalespib and Hsp90 inhibitors in other
malignancies.
项目摘要
胶质母细胞瘤是一种致命的原发性脑肿瘤,治疗选择有限。目前的标准疗法,
联合放化疗(chemoRT)与替莫唑胺(TMZ),一种烷化剂,
生存期仅16-18个月。迫切需要新的治疗方法,特别是那些可以克服
对化疗耐药。癌细胞发展出复杂的抵抗机制,使它们能够在
传统疗法的效果。其中一个进化上保守的机制是热休克反应
(HSR)其可以在不利的环境条件下部署几种不同的防御过程。
HSR由热休克蛋白(HSP)介导,热休克蛋白是一类穿梭并
将客户癌蛋白配置为适当的功能状态。在初步研究中,我们表明,onalb,a
热休克蛋白90(Hsp 90)的新型长效抑制剂,热休克蛋白90是癌细胞中HSR的关键介质,
在胶质瘤中阻断肿瘤生长、侵袭和血管生成,这表明在胶质瘤中具有强大的独立的
抗肿瘤作用与此相关的是,onalb使胶质瘤细胞对TMZ和RT在患者源性肿瘤中敏感。
(PDX)细胞系以及在斑马鱼和小鼠颅内胶质瘤动物模型中。根据这些数据,在
我们建议通过NCI资助的成人脑肿瘤联盟进行I期临床试验,
确定在成人新感染者中onalb与chemoRT联合治疗的最大耐受剂量
诊断为GBM。我们还建议通过以下方式进行关键的相关组织和血浆研究:
具体目标:目标1将确定onalbib联合化疗RT和辅助替莫唑胺的MTD
并将确定onalb是否可以穿过血脑屏障,并达到足够的浓度,
增强和非增强胶质瘤组织与血浆水平相比。目标2将决定
通过评估onalb是否可以抑制其在人体中的靶点Hsp 90,来评估onalb的药效学作用
本试验中获得的GBM组织以及这种抑制是否会影响其伴侣癌蛋白客户
特别是那些与DNA修复和细胞存活对抗RT和TMZ作用相关的。在目标3中,我们
使用PDX颅内胶质瘤模型和器官型人胶质瘤切片进行联合临床试验,
确定onalb效应的敏感性和抗性机制,以提供有助于
修改后续的II期试验。这是Hsp 90抑制剂在脑肿瘤中的首次人体试验,
第一个将Hsp 90抑制剂与针对GBM的化学和放射疗法联合收割机。成功完成
这项试验将使我们能够进行II期疗效试验(由NRG肿瘤学批准),并将提供
全面的PK和PD数据,可以帮助开发onalb和Hsp 90抑制剂,
恶性肿瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VINAY K PUDUVALLI其他文献
VINAY K PUDUVALLI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VINAY K PUDUVALLI', 18)}}的其他基金
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂
- 批准号:
10480888 - 财政年份:2019
- 资助金额:
$ 56.84万 - 项目类别:
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂
- 批准号:
10397791 - 财政年份:2019
- 资助金额:
$ 56.84万 - 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
- 批准号:
8731813 - 财政年份:2012
- 资助金额:
$ 56.84万 - 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
- 批准号:
8846550 - 财政年份:2012
- 资助金额:
$ 56.84万 - 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
- 批准号:
8459885 - 财政年份:2012
- 资助金额:
$ 56.84万 - 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
- 批准号:
8300649 - 财政年份:2012
- 资助金额:
$ 56.84万 - 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
- 批准号:
7167160 - 财政年份:2006
- 资助金额:
$ 56.84万 - 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
- 批准号:
7340756 - 财政年份:2006
- 资助金额:
$ 56.84万 - 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
- 批准号:
7749939 - 财政年份:2006
- 资助金额:
$ 56.84万 - 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
- 批准号:
7033212 - 财政年份:2006
- 资助金额:
$ 56.84万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 56.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 56.84万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 56.84万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 56.84万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 56.84万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 56.84万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 56.84万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 56.84万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 56.84万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 56.84万 - 项目类别: